Immunotherapy of human retinoblastoma with RGNTF-monoclonal antibody using nude mice as model
Ren, F.; Zhou, M.H.
Zhonghua Zhong Liu Za Zhi 14(5): 323-326
1992
ISSN/ISBN: 0253-3766 PMID: 1291287 Document Number: 391351
Retinoblastoma in nude mice as an animal model was developed by injecting cultured human retinoblastoma cell line(Rb) Y79 into the anterior chamber of eyeball. It was treated by direct injection of RGNTF-McAb into the Rb tumor. Ten out of 30 eyeballs with Rb inoculation did not develop tumor (32% inhibition) if Rb cell suspension was mixed with the RGNTF-McAb before injection; whereas in the control, all 40 but 3 eyeballs developed tumor (7%) when Rb cell suspension alone had been injected. This 32% of inhibition of Rb tumor formation by RGNTF-McAb was very significant (T gt 2.58, P lt 0.01). The results of immunotherapy of 46 eyeballs with Rb tumor developed 10 days after inoculation by RGNTF-McAb for 2 months revealed that the proportion of grade III apprx IV tumors before and after therapy reduced from 53% to 26% and that of grade I apprx II tumors increased from 47% to 74%. Feulgen DNA staining of tumor sections after therapy revealed that the average DNA contents in Rb cells decreased significantly (P lt 0.01) from 16.2+-2.6 in grade III apprx IV to 5.3+-1.2 in grade I apprx II compared to that of the untreated control 18.8+-3.2. Numerous white cells infiltrating the Rb tumor, hyperplasia of fibrous tissues, and no spreading and metastasis of the tumor tissue were observed in the treated eyeballs; whereas Rb tumor was spreading to the optic nerve and superior colliculus in the untreated eyeballs. Therefore, the RGNTF-McAb can not only inhibit the growth of Rb cells but also limit their spreading and metastasis. These results can provide a basis for immunotherapy of Rb tumor with this RGNTF-McAb.